Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s Why

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $18.02, but opened at $18.91. Daiichi Sankyo shares last traded at $18.2650, with a volume of 9,132 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on DSNKY shares. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Daiichi Sankyo currently has an average rating of “Reduce”.

Daiichi Sankyo Stock Performance

The stock has a market capitalization of $34.07 billion, a price-to-earnings ratio of 21.27, a price-to-earnings-growth ratio of 2.47 and a beta of -0.11. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.92 and a quick ratio of 1.64. The stock has a 50-day moving average of $17.18 and a 200 day moving average of $17.34.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.